v3.25.2
Commitments and Contingencies (Details Narrative) - Sonnet BioTherapeutics Holdings, Inc. [Member]
€ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 31, 2024
Apr. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2025
EUR (€)
Sep. 30, 2024
EUR (€)
Apr. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jan. 31, 2019
USD ($)
Jul. 31, 2012
USD ($)
Loss Contingencies [Line Items]                                
Acquired in-process research             $ 12,000 $ 12,000 $ 12,000 $ 443,250            
Discovery Collaboration Agreements [Member]                                
Loss Contingencies [Line Items]                                
License fees         $ 0 $ 0 0 0                
Discovery Collaboration Agreements [Member] | XOMA [Member]                                
Loss Contingencies [Line Items]                                
MilestonePayments                               $ 3,800,000
Discovery Collaboration Agreements [Member] | XOMA [Member] | In Process Research and Development [Member]                                
Loss Contingencies [Line Items]                                
License fees   $ 500,000     0 0 0 0 $ 0 0            
Cellca Agreement [Member]                                
Loss Contingencies [Line Items]                                
MilestonePayments         600,000   $ 600,000                  
Description of milestone payments             The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.   The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.              
Cellca Agreement [Member] | Maximum [Member]                                
Loss Contingencies [Line Items]                                
MilestonePayments                             $ 700,000  
Payment for annual license fee obligation         600,000   $ 600,000                  
Cellca Agreement [Member] | Minimum [Member]                                
Loss Contingencies [Line Items]                                
Payment for annual license fee obligation         100,000   100,000                  
Cellca Agreement [Member] | In Process Research and Development [Member]                                
Loss Contingencies [Line Items]                                
License fees         0 0 0 0                
Commercial product license fee   100,000                            
The Cellca Agreement [Member]                                
Loss Contingencies [Line Items]                                
MilestonePayments                 $ 600,000              
The Cellca Agreement [Member] | Maximum [Member]                                
Loss Contingencies [Line Items]                                
Payment for annual license fee obligation                 600,000              
The Cellca Agreement [Member] | Minimum [Member]                                
Loss Contingencies [Line Items]                                
Payment for annual license fee obligation                 100,000              
The Cellca Agreement [Member] | In Process Research and Development [Member]                                
Loss Contingencies [Line Items]                                
License fees                 0 0            
Commercial product license fee   $ 100,000                            
The Brink Agreement [Member]                                
Loss Contingencies [Line Items]                                
License fees         0 0 12,000 12,000                
Commercial product license fee         100,000   100,000   100,000              
Annual license fee                         $ 12,000      
Cell line storage fee             12,000                  
The Brink Agreement [Member] | In Process Research and Development [Member]                                
Loss Contingencies [Line Items]                                
License fees                 12,000 12,000            
Development license fee         100,000   100,000   100,000              
InvivoGen Agreement [Member]                                
Loss Contingencies [Line Items]                                
License fees           0   0 0 0            
Payment for annual license fee obligation         100,000   100,000   100,000   € 0.1 € 0.1        
InvivoGen Agreement [Member] | In Process Research and Development [Member]                                
Loss Contingencies [Line Items]                                
License fees         100,000   100,000                  
ProteoNic Agreement [Member]                                
Loss Contingencies [Line Items]                                
MilestonePayments         200,000   200,000       € 0.2          
License fees         0   0   0 0            
ProteoNic Agreement [Member] | In Process Research and Development [Member]                                
Loss Contingencies [Line Items]                                
License fees     $ 24,600                          
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member]                                
Loss Contingencies [Line Items]                                
MilestonePayments       $ 1,000,000.0 0 0 0 0 0         $ 1,000,000.0    
Acquired in-process research       100,000         100,000              
Evaluation milestone recognized       $ 300,000                        
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member] | Research and Development Expense [Member]                                
Loss Contingencies [Line Items]                                
License fees         0 $ 0 0 $ 0 $ 0 $ 300,000            
Alkem Agreement [Member]                                
Loss Contingencies [Line Items]                                
MilestonePayments         $ 1,000,000.0   1,000,000.0                  
License fees             $ 100,000                  
SOC Agreement [Member]                                
Loss Contingencies [Line Items]                                
Agreements description the Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur, payable to the SOC, a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third party partnership.